Live biotherapeutics are key early-stage clinical candidates of 4D Pharma, building on increasing knowledge of the microbiome. In the latest episode of Business of Biotech, 4D Pharma’s CEO Duncan Peyton explains how new insights into the microbiome are driving innovations that could impact patients with a broad range of conditions and care needs.
According to Pharmaceutical Online, “Peyton is leading the effort to understand how the health of the microbiome relates to a wide range of diseases, including immuno-oncology, central nervous system disorders, respiratory disease, auto immune indications, and gastro intestinal disease. 4D pharma is even working on a live biotherapeutic vaccine platform. Join Duncan on this episode of the Business of Biotech as we discuss this new frontier of therapeutic exploration.”
Listen to the podcast by clicking here.
(Source: Pharmaceutical Online, May 13th, 2022)